LONDON, United Kingdom — Jamaica is set to benefit from a donation of 300,000 AstraZeneca COVID-19 vaccines from the United Kingdom.

UK Foreign Secretary, Dominic Raab announced Wednesday that nine million of the University of Oxford-AstraZeneca COVID-19 vaccine will be delivered around the world to assist in the fight against the pandemic.

This is the first portion of the 100 million vaccines the prime minister pledged the UK would share within the next year at last month’s G7 in Cornwall, with 30 million due to be sent by the end of the year. At least 80 million of the 100 million doses will go to COVAX, with the rest going to countries directly. The donations will help meet the pledge that G7 leaders made to vaccinate the world and end the pandemic in 2022.

The foreign secretary announced on Wednesday that five million doses are being offered to COVAX, the scheme to ensure equitable, global access to COVID-19 vaccines. COVAX will urgently distribute them to lower-income countries via an equitable allocation system which prioritises delivering vaccines to people who most need them. Another four million doses will be shared directly with countries in need including Indonesia, Jamaica and Kenya.

Indonesia will receive 600,000 doses, 300,000 will be sent to Jamaica and 817,000 are to be transported to Kenya, among other countries.

This week’s deployment will help meet the urgent need for vaccines from countries around the world, including in Africa, South East Asia and the Caribbean. These regions are experiencing high levels of COVID-19 cases, hospitalisations and deaths.

“The UK is sending nine million doses of AstraZeneca vaccine, the first batch of the 100 million doses we’ve pledged, to get the most vulnerable parts of the world vaccinated as a matter of urgency. We’re doing this to help the most vulnerable, but also because we know we won’t be safe until everyone is safe,” Raab said.

The statement disclosed that the UK has been at the forefront of the global response to COVID-19, including through investing £90 million to support the development of the Oxford-AstraZeneca vaccine. Over half a billion doses of the Oxford-AstraZeneca vaccine have been delivered at a non-profit price globally, with two-thirds going to lower- and middle-income countries.

The UK also kick-started efforts to establish COVAX in 2020, providing a total of £548 million to fund vaccines for lower income countries. The scheme has delivered more than 152 million vaccine doses to over 137 countries and territories, including in 83 lower-middle income countries. 65 per cent of the initial vaccine doses have been Oxford-AstraZeneca. COVAX aims to deliver 1.8 billion vaccines to lower-income countries around the world by early 2022.

“This is a global pandemic and COVID-19 vaccines are the best way to protect people and prevent the emergence of new variants. We want to make sure developing countries can build a wall of defence against the virus as we have in the UK through our vaccine rollout,” said Health Secretary Sajid Javid.

“The UK is one of the largest donors to COVAX and this donation is part of our pledge to send 100 million vaccines to some of the world’s poorest countries. The Government has secured enough doses for all UK residents, crown dependencies and overseas territories to support our ongoing vaccination programme and booster programme,” he continued.

Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance, which is co-leading COVAX alongside the World Health Organization and the Coalition for Epidemic Preparedness Innovations, added,

“The UK has been a steadfast supporter of COVAX since its inception and this announcement comes at an important time. Global vaccine demand is far outstripping supply, leaving millions of the most vulnerable unprotected, while higher vaccine coverage worldwide is one of our best shields against new variants. In this pandemic nobody is safe until everyone is safe.”

Sir Mene Pangalos, Executive Vice President BioPharmaceuticals R&D at AstraZeneca, stated,

“Each day we’re making progress in our mission to change the course of this pandemic by providing broad and equitable access to AstraZeneca’s vaccine. We are proud that over 80 per cent of countries across the world have received doses of our vaccine, with two thirds supplied to lower middle income and low income countries.

“The close collaboration between the UK Government and our academic and industry partners is critical to ensure we deliver vaccines at speed and protect as many people as possible against this deadly virus.”